Cytokinetics Inc (CYTK) stock
CYTKNasdaqPharmaceutical PreparationsFiscal year ends December 31
$51.46+0.14 (+0.27%)
Close on Nov 19, 2026Market cap $7.15BP/E –Yield –
Cytokinetics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Cytokinetics's free cash flow for the twelve months ending Jun 30, 2026 was -$580.72M. For fiscal 2025 it was -$534.82M. The highest annual figure on record is $35.39M in fiscal 2016.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$534.82M | – |
| FY2024 | Dec 31, 2024 | -$399.80M | – |
| FY2023 | Dec 31, 2023 | -$415.75M | – |
| FY2022 | Dec 31, 2022 | -$310.85M | – |
| FY2021 | Dec 31, 2021 | -$191.39M | – |
| FY2020 | Dec 31, 2020 | -$2.11M | – |
| FY2019 | Dec 31, 2019 | -$93.53M | – |
| FY2018 | Dec 31, 2018 | -$102.10M | – |
| FY2017 | Dec 31, 2017 | -$104.64M | -395.7% |
| FY2016 | Dec 31, 2016 | $35.39M | +718.9% |
| FY2015 | Dec 31, 2015 | $4.32M | – |
| FY2014 | Dec 31, 2014 | -$45.95M | – |
| FY2013 | Dec 31, 2013 | -$8.26M | – |
| FY2012 | Dec 31, 2012 | -$33.56M | – |
| FY2011 | Dec 31, 2011 | -$46.04M | – |
| FY2010 | Dec 31, 2010 | -$45.32M | -676.2% |
| FY2009 | Dec 31, 2009 | $7.87M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$164.17M | – |
| Q1 FY2026 | Mar 31, 2026 | -$151.39M | – |
| Q4 FY2025 | Dec 31, 2025 | -$148.30M | – |
| Q3 FY2025 | Sep 30, 2025 | -$116.86M | – |
| Q2 FY2025 | Jun 30, 2025 | -$132.38M | – |
| Q1 FY2025 | Mar 31, 2025 | -$137.28M | – |
| Q4 FY2024 | Dec 31, 2024 | -$66.86M | – |
| Q3 FY2024 | Sep 30, 2024 | -$102.20M | – |
| Q2 FY2024 | Jun 30, 2024 | -$101.23M | – |
| Q1 FY2024 | Mar 31, 2024 | -$129.51M | – |
| Q4 FY2023 | Dec 31, 2023 | -$74.11M | – |
| Q3 FY2023 | Sep 30, 2023 | -$96.43M | – |
| Q2 FY2023 | Jun 30, 2023 | -$122.52M | – |
| Q1 FY2023 | Mar 31, 2023 | -$122.69M | – |
| Q4 FY2022 | Dec 31, 2022 | -$101.40M | – |
| Q3 FY2022 | Sep 30, 2022 | -$90.37M | – |
| Q2 FY2022 | Jun 30, 2022 | -$91.33M | – |
| Q1 FY2022 | Mar 31, 2022 | -$27.75M | – |
| Q4 FY2021 | Dec 31, 2021 | -$62.49M | -237.1% |
| Q3 FY2021 | Sep 30, 2021 | -$54.47M | -562.6% |
| Q2 FY2021 | Jun 30, 2021 | -$38.29M | – |
| Q1 FY2021 | Mar 31, 2021 | -$36.15M | – |
| Q4 FY2020 | Dec 31, 2020 | $45.60M | – |
| Q3 FY2020 | Sep 30, 2020 | $11.78M | – |
| Q2 FY2020 | Jun 30, 2020 | -$28.30M | – |
| Q1 FY2020 | Mar 31, 2020 | -$31.18M | – |
| Q4 FY2019 | Dec 31, 2019 | -$20.36M | – |
| Q3 FY2019 | Sep 30, 2019 | -$21.27M | – |
| Q2 FY2019 | Jun 30, 2019 | -$24.73M | – |
| Q1 FY2019 | Mar 31, 2019 | -$27.16M | – |
| Q4 FY2018 | Dec 31, 2018 | -$12.54M | – |
| Q3 FY2018 | Sep 30, 2018 | -$32.59M | – |
| Q2 FY2018 | Jun 30, 2018 | -$26.91M | – |
| Q1 FY2018 | Mar 31, 2018 | -$30.07M | – |
| Q4 FY2017 | Dec 31, 2017 | -$24.85M | -132.3% |
| Q3 FY2017 | Sep 30, 2017 | -$25.93M | – |
| Q2 FY2017 | Jun 30, 2017 | -$31.52M | – |
| Q1 FY2017 | Mar 31, 2017 | -$22.33M | – |
| Q4 FY2016 | Dec 31, 2016 | $76.98M | – |
| Q3 FY2016 | Sep 30, 2016 | -$12.43M | – |
See a number that looks wrong?